Precision Medicine Group

In this issue of our Precision Manufacturing newsletter, our experts highlight the strategic importance of portfolio management in the cell and gene industry. Click below to read more and subscribe today! #CellTherapy #GeneTherapy #PortfolioManagement

Struggling to find the right biospecimens? Have a highly exacting biospecimens need? A custom collection can provide specimens precisely aligned to your project's requirements - all handled by our veteran team. Discover more: https://lnkd.in/e42_u9ma #biospecimens #precisionmedicine

?? Major Collaboration Update! Precision for Medicine is working with SOPHiA GENETICS and Boundless Bio to revolutionize clinical trials with their novel platform. Precision for Medicine helped validate a novel assay to enable advanced diagnostic workflows for Boundless Bio’s POTENTIATE trial, expediting patient selection for ecDNA-driven cancer therapies. Read more about the partnership and breakthrough on the Precision for Medicine press release! https://hubs.ly/Q02P5Kjk0? #precisionmedicine #clinicaltrials #datadrivenmedicine #SOPHiAGenetics #BoundlessBio

Meet Precision's Harpreet Singh, MD, Chief Medical Officer, and Amanda Knapp, Director of Business Development, at the World Conference on Lung Cancer, September 7-10! Reach out to Harpreet or Amanda to set up time to speak. More here: https://hubs.ly/Q02NR3c_0

??FDA Oncology Roundup: August Precision CMO, Harpreet Singh, MD, highlights three recent regulatory decisions and their potential impact on oncology research. Key approvals: -AstraZeneca's Aegean Trial saw Durvalumab approved for resectable lung cancer -Janssen’s innovative combo of Lazertinib and Amivantamab for EGFR-mutated lung cancer -New treatment for low-grade gliomas with IDH1/2 mutations What this means for drug developers: -Consider perioperative strategies earlier in development plans -Look to invest in robust biomarker programs alongside drug development -Plan for more complex, multi-arm trials to demonstrate added value of combination approaches How might these approvals affect your oncology development? #FDA #Oncology #ClinicalTrials #immunotherapy

Dealing with biospecimens burnout? Receiving poor quality or poorly annotated samples? Precision for Medicine's biorepositories have over 10 million samples, from biofluids to tissues. We're here to help get you what you need: https://hubs.ly/Q02NzXd_0 #biospecimens #precisionmedicine

We’ve already racked up over 60 million steps and we're just getting started! Our third annual "Just Move" wellness challenge is in full swing, with the Precision team actively participating in photo and fitness challenges for a shot at exciting prizes and funds for charity. Through our unique #PatientPowerUp photo challenges, we're supporting Achilles International, Cradles to Crayons, Cystic Fibrosis Foundation, Lupus Research Alliance , and ZERO Prostate Cancer. Our goal is to have 100% participation and over $20,000 raised for charitable causes. Check out this collage from our second photo challenge theme, family fitness! #patientfocused #peoplefirst #stepchallenge #community

Successful project planning and controls in biotech manufacturing requires a comprehensive approach. In this issue of our Precision Manufacturing newsletter, our experts outline four key steps for biotech manufacturers to efficiently navigate the challenging path from drug discovery to manufacturing and marketing. Click below to read more and subscribe today! #projectcontrols #projectplanning #biotech

New website https://lnkd.in/eaZdfisZ. Same unusual name. Too busy to visit the website or watch the video? Connect with Teresa Pokladowski, and find out how your complex development project can go the distance with Precision.

What does the FDA's accelerated approval of adagrasib mean for colorectal cancer patients and drug developers? Dr.?Harpreet Singh, MD, our Chief Medical Officer and former FDA oncology division director, breaks down this significant development and its implications. Key points: - FDA granted accelerated approval for adagrasib + cetuximab on June 21st - First KRAS G12C targeting drug approved for colorectal cancer - 34% overall response rate in the single-arm KRYSTAL-1 trial - Targets ~4% of colorectal cancer patients with KRAS G12C mutations Dr. Singh's insights: - KRAS was previously considered "undruggable" in colorectal cancer - This approval addresses a high unmet need in a specific patient subgroup - KRYSTAL-10 confirmatory trial is ongoing to potentially convert to full approval This breakthrough could reshape targeted therapies in colorectal cancer. What are your thoughts on this accelerated approval? How might it impact oncology drug development or patient care? #OncologyTrials #DrugDevelopment #ColorectalCancer #PrecisionMedicine Follow Dr. Harpreet Singh, MD Singh for more expert analysis on breakthrough treatments and FDA insights.